Company / SG&A Expense
Edgewise Therapeutics, Inc. SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$40.0M
FY2025
5-year range
$11.0M / $40.0M
FY2021-FY2025
Trend
+25.6%
vs FY2024
Sector context
#173 of 213
Health Care
What the data says
Edgewise Therapeutics, Inc.'s sg&a expense of $40M is lower than 81% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 5 consecutive years, from $2M in FY2020 to $40M in FY2025.
Based on SEC 10-K filings.
$40M in FY2025 with a 5-year CAGR of +78.5%.
Increased from $23M to $40M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +31.4%
- 5-Year CAGR
- +78.5%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 213This company $40.0M Sector average $722.3M
▼
-94.5% below sector average
Key checks
Key Insights
- Edgewise Therapeutics, Inc.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +78.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 25.6% year-over-year.
- Ranks #173 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $40.0M | +25.6% |
| FY2024 | $31.9M | +35.9% |
| FY2023 | $23.5M | +33.1% |
| FY2022 | $17.6M | +59.9% |
| FY2021 | $11.0M | +399.1% |
| FY2020 | $2.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026